Abstract: 
Cirrhosis is one of the chronic generalised disease and has a variety of clinical manifestations and complications some of which can be a life threatening. This results in decrease in hepatocellular mass and thus functions. It is 12^th leading cause of death in United States. Hepatic stellate cells (HSC) plays a crucial role in the development of liver fibrosis because of their prominent role in extracellular matrix production, regulation of vascular tone, and production of inflammatory mediators such as transforming growth factor-b (TGF-b) and platelet-derived growth factor (PDGF). Therefore, these cells are major target for the treatment of Cirrhosis. Anti-fibrotic drugs are not efficiently taken up by HSC or may produce unwanted side-effects outside the liver. Cell-specific delivery can provide a solution to these problems, but a specific drug carrier for HSC has not been described until now. The mannose 6-phosphate/insulin-like growth factor II (M6P/IGF-II) receptor, which is expressed in particular upon HSC during fibrosis, may serve as a target-receptor for a potential carrier. The primary aim of drug targeting is to manipulate the whole body distribution of drugs, that is, to prevent distribution to non-target cells and concomitantly increase the drug concentration at the targeted site. Carrier molecules are designed for their selective cellular uptake, taking advantage of specific receptors or binding sites present on the surface membrane of the target cell.

Keywords: Liver, Cirrhosis, Hepatic Stellate Cells Targeting.